Copper deficiency in patients with cystinosis with cysteamine toxicity

J Pediatr. 2013 Sep;163(3):754-60. doi: 10.1016/j.jpeds.2013.03.078. Epub 2013 May 4.

Abstract

Objectives: To assess whether copper deficiency plays a role in the recently described cysteamine toxicity in patients with cystinosis, and to examine whether polymorphisms in copper transporters, lysyl oxidase, and/or type I procollagen genes could be responsible for the occurrence of cysteamine toxicity in a small subset of patients with cystinosis.

Study design: Thirty-six patients with cystinosis were included: 22 with Fanconi syndrome (including 7 with cysteamine toxicity), 12 after renal transplantation, 1 receiving hemodialysis, and 1 with ocular cystinosis. Serum copper and ceruloplasmin levels and urinary copper/creatinine ratio were measured. Genes ATP7A and CTR1 (encoding copper transporters), LOX (encoding lysyl oxidase), and COL1A1 and COL1A2 (encoding type I procollagen) were analyzed in patients with (n = 6) and without (n = 5) toxicity. Fibroblast (pro)collagen synthesis was compared in patients with (n = 3) and those without (n = 2) cysteamine toxicity.

Results: All 22 patients with Fanconi syndrome had increased urinary copper excretion. Serum copper and ceruloplasmin levels were decreased in 9 patients, including all 7 patients with cysteamine toxicity. No specific sequence variations were associated with toxicity. All fibroblasts exhibited normal (pro)collagen synthesis.

Conclusion: Patients with cystinosis with cysteamine toxicity demonstrate copper deficiency. This can cause decreased activity of lysyl oxidase, the enzyme that generates the aldehydes required for collagen cross-linking. Thus, copper supplementation might prevent cysteamine toxicity.

Keywords: FS; Fanconi syndrome.

MeSH terms

  • Adenosine Triphosphatases / genetics
  • Adolescent
  • Adult
  • Biomarkers / metabolism
  • Cation Transport Proteins / genetics
  • Ceruloplasmin / metabolism
  • Child
  • Child, Preschool
  • Collagen / metabolism
  • Collagen Type I / genetics
  • Collagen Type I, alpha 1 Chain
  • Copper / deficiency*
  • Copper / metabolism
  • Copper Transporter 1
  • Copper-Transporting ATPases
  • Cysteamine / adverse effects*
  • Cysteamine / therapeutic use
  • Cystinosis / complications*
  • Cystinosis / drug therapy
  • Cystinosis / genetics
  • Cystinosis / metabolism
  • Fanconi Syndrome / complications
  • Fanconi Syndrome / drug therapy
  • Fanconi Syndrome / genetics
  • Fanconi Syndrome / metabolism
  • Female
  • Genetic Markers
  • Humans
  • Male
  • Polymorphism, Genetic
  • Protective Agents / adverse effects*
  • Protective Agents / therapeutic use
  • Protein-Lysine 6-Oxidase / genetics
  • Renal Agents / adverse effects*
  • Renal Agents / therapeutic use
  • Sequence Analysis, DNA
  • Young Adult

Substances

  • Biomarkers
  • Cation Transport Proteins
  • Collagen Type I
  • Collagen Type I, alpha 1 Chain
  • Copper Transporter 1
  • Genetic Markers
  • Protective Agents
  • Renal Agents
  • SLC31A1 protein, human
  • Cysteamine
  • Copper
  • Collagen
  • Ceruloplasmin
  • Protein-Lysine 6-Oxidase
  • Adenosine Triphosphatases
  • ATP7A protein, human
  • Copper-Transporting ATPases